Inside the research
Boston Scientific Corporation
BSX Research profile · latest available data
Price overview
$43.92
▼ -0.76 (-1.7%)
| 52w hi | $104.98 |
|---|---|
| 52w lo | $42.63 |
| Vol | 15.21M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.18
| Short | -0.51 |
|---|---|
| Medium | -0.09 |
| Long | +0.30 |
computed 2026-09-27
Key fundamentals
Boston Scientific Corporation
Healthcare · Medical Devices
| Market cap | $63.65B |
|---|---|
| Enterprise value | $75.98B |
| Trailing P/E | 17.78x |
| Forward P/E | 12.87x |
| EV / EBITDA | 13.30x |
| P / S (ttm) | 3.03x |
| Profit margin | 17.5% |
| Return on equity | 15.3% |
| Revenue growth | +7.5% |
| Earnings growth | +15.1% |
| Debt / equity | 50.15 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.31 | |
| Sector | +0.08 | |
| Technical | -0.34 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Risk Metrics
| Beta vs SPX | 0.57 |
|---|---|
| Corr SPX | 0.29 |
| Annual vol | 31.6% |
| Annual ret | -27.2% |
| Sharpe | -0.86 |
| Max DD | -60.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $85.19 |
|---|---|
| High / Low | $110.00 / $60.00 |
| Median | $84.50 |
| Analysts | 32 |
| Strong Buy | 8 | |
|---|---|---|
| Buy | 23 | |
| Hold | 2 | |
| Sell | 0 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-04-23 | Wells Fargo | → Overweight |
| 2026-04-23 | Truist Securities | → Buy |
| 2026-04-23 | RBC Capital | → Outperform |
| 2026-04-23 | Needham | → Buy |
| 2026-04-23 | Goldman Sachs | → Buy |
| 2026-04-23 | Evercore ISI Group | → Outperform |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-07-29 | Earnings Release, Exhibits | read |
| 2026-07-27 | Restructuring | read |
| 2026-05-18 | Other Material Event, Exhibits | read |
| 2026-05-18 | Other Material Event, Exhibits | read |
| 2026-05-05 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-04-22 | Earnings Release, Exhibits | read |
| 2026-03-30 | Other Material Event, Exhibits | read |
| 2026-02-26 | Material Agreement, Termination of Agreement… | read |
| 2026-02-23 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-02-05 | Officer / Director Change | read |
| 2026-02-04 | Earnings Release, Exhibits | read |
| 2026-01-15 | Material Agreement, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 94.8% |
| HHI | 2,912 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $2.99B | 70.11M |
| Fidelity / FMR LLC | $1.95B | 45.70M |
| Capital Research / Capital World | $711.51M | 16.67M |
| Citadel Advisors | $433.43M | 10.16M |
| AQR Capital Management | $413.22M | 9.68M |
| Millennium Management | $232.13M | 5.94M |
| Renaissance Technologies | $102.94M | 2.41M |
| Bridgewater Associates | $18.87M | 442.04K |
| T. Rowe Price Group | $301.77K | 7.07M |
As of 2026-06-30
Federal Contracts
| Amount | Agency | Description |
|---|---|---|
| $4.68M | Department of Defense | THERASPHERE |
| $4.04M | Department of Veterans Affairs | Y90 GLASS MICROSPHERES |
| $2.92M | Department of Veterans Affairs | THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION |
| $1.38M | Department of Veterans Affairs | YTTRIUM-90 THERASPHERES |
| $1.36M | Department of Veterans Affairs | Y90 THERASPHERE |
| $1.36M | Department of Veterans Affairs | CARDIAC HOLSTER MONITORING SERVICES |
| $1.10M | Department of Health and Human Services | POTASSIUM IODINE TABS |
| $1.04M | Department of Veterans Affairs | Y90 THERESPHERE |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $16.75B | +4.6% | |
| Gross profit | $11.49B | +4.6% | |
| Operating income | $2.60B | +72.7% | |
| Cash from ops | $3.44B | +9.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $44.68 | $44.84 | $43.33 | $43.92 | 15.21M |
| Sep 24 | $44.65 | $45.16 | $44.46 | $44.68 | 17.30M |
| Sep 23 | $45.00 | $45.74 | $43.99 | $44.62 | 18.56M |
| Sep 22 | $44.70 | $45.08 | $44.04 | $44.92 | 21.07M |
| Sep 21 | $42.98 | $43.81 | $42.72 | $43.72 | 25.00M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →